ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondyloarthritis"

  • Abstract Number: 0584 • ACR Convergence 2025

    Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.

    Rodrigo García Salinas1, Nataly Mejia2, Santiago Ruta3 and Sebastian Magri4, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano de La Plata, La Plata, Argentina, 3Hospital San Martin de La Plata, La Plata, Argentina, 4Hospital Italiano La Plata, Melchor Romero, Argentina

    Background/Purpose: The concept of difficult-to-Manage axial spondyloarthritis (axSpA D2M), recently introduced by ASAS, describes patients who fail ≥2 lines of b-tsDMARDs treatment and remain active…
  • Abstract Number: 2365 • ACR Convergence 2025

    Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials

    Joseph F Merola1, Laura Coates2, Atul Deodhar3, Alice B. Gottlieb4, Enrique R. Soriano5, Barbara Ink6, Rajan Bajracharya6, Jason Coarse7 and Philip J. Mease8, 1Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 3Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 4Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, 5Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires and University Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6UCB, Slough, England, United Kingdom, 7UCB, Morrisville, NC, 8Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA

    Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A, has demonstrated sustained efficacy to 3 years (yrs) in…
  • Abstract Number: 2322 • ACR Convergence 2025

    Gender-related Differences in Peripheral and Axial Spondyloarthritis

    Mehmet Tuncay Duruöz1, Halise Hande Gezer1, İlknur Aktaş2, Servet Akar3, Nilay Şahin4, Özgür Akgül5, Sami Hizmetli6, Meltem Alkan Melikoğlu7, Umut Kalyoncu8, Erhan Çapkın9, fatma Gülçin Ural10, Figen Yılmaz11, Sebnem ATAMAN12 and İlhan Sezer13, 1Marmara University Medical School PMR Department, Rheumatology Division, Istanbul, Turkey, 2Istanbul Fatih Sultan Mehmet Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, 3Department of Medicine, Izmir Katip Çelebi University School of Medicine, Izmir, Turkey, 4Balikesir University School of Medicine, PMR, Turkey, Balıkesir, Turkey, 5Manisa Celal Bayar University School of Medicine, Rheumatology, Turkey, Manisa, Turkey, 6Sivas Cumhuriyet University School of Medine, Rheumatology, Turkey, Sivas, Turkey, 7Erzurum Atatürk University School of Medicine, Rheumatology, Turkey, Erzurum, Turkey, 8Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey, Ankara, Turkey, 9Karadeniz Teknik University School of Medicine, PMR, Turkey, Trabzon, Turkey, 10Ankara Yildirim Beyazit University School of Medicine, PMR, Turkey, Ankara, Turkey, 11Istanbul Sisli Etfal Training and Research Hospital, PMR, Turkey, Istanbul, Turkey, 12Ankara University School of Medicine, Rheumatology, Turkey, Ankara, Turkey, 13Akdeniz University School of Medicine, Rheumatology, Turkey, Antalya, Turkey

    Background/Purpose: This study sought to compare clinical characteristics between female and male patients with spondyloarthritis (SpA) in a Turkish population.Methods: This study included 489 peripheral…
  • Abstract Number: 1962 • ACR Convergence 2025

    Imaging findings in patients with enteropathic spondyloarthritis

    Marika Bodnárová1, Lucia Ondrejčáková2, Tomáš Grega3, Ladislav Šenolt4, Karel Pavelka5 and Kristýna Bubová1, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Hlavni mesto Praha, Czech Republic, 3Military University Hospital Prague, Prague, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Enteropathic spondyloarthritis (eSpA) is a subtype of SpA associated with inflammatory bowel disease (IBD). Sacroiliac joints (SIJs) involvement is common in eSpA but often…
  • Abstract Number: 1444 • ACR Convergence 2025

    Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis

    Jeffrey Curtis1, Genevieve Gauthier2, Lara Fallon3, David Gruben3, You-Li Ling4, Matthew Brouillette3, Arne Yndestad5, Yu hong6 and Mona Kelkar6, 1Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 2Pfizer Canada ULC, Kirkland, QC, Canada, Montreal, Canada, 3Pfizer Inc, New York, NY, USA, New York, 4Pfizer Inc, New York, NY, USA, New York, NY, 5Pfizer Inc, Oslo, Norway, Oslo, Norway, 6Genesis Research Group, Hoboken, NJ, USA, New York

    Background/Purpose: : In the context of an expanding therapeutic landscape and absence of head-to-head trials in axial spondyloarthritis (axSpA), data on direct comparison of effectiveness…
  • Abstract Number: 1062 • ACR Convergence 2025

    Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort

    Diego Benavent1, Mar Tapia2, Daniel Bernabeu2, Victor Muley2, Manuel Juárez3, Alejandro Balsa4, Chamaida Plasencia-Rodríguez4 and Victoria Navarro-Compan5, 1Hospital Universitari de Bellvitge, Madrid, Spain, 2HU La Paz, Madrid, Spain, 3Rheumatology Unit, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, 4Hospital Universitario La Paz, Madrid, Spain, 5Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain

    Background/Purpose: Sex-related differences in axial spondyloarthritis (axSpA) have been described regarding clinical features, disease burden, and particularly patient-reported outcomes. These differences influence patient management, including…
  • Abstract Number: 0548 • ACR Convergence 2025

    Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI

    Seonyoung Kang1, Yunseo Kim2, Seulkee Lee3, Myung Jin Chung4, Hyungjin Kim5, Jaejoon Lee4, Hakje Yoo6 and Hoon-Suk Cha4, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam-gu, Seoul, Republic of Korea, 2Samsung Medical Center, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea, 3Samsung Medical Center, Sunkyunkwan University School of Medicine, Seoul, South Korea, 4Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 5Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 6Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea

    Background/Purpose: The Assessment of SpondyloArthritis International Society (ASAS) criteria define positive MRI findings based on the presence of bone marrow edema (BME) in the sacroiliac…
  • Abstract Number: 0483 • ACR Convergence 2025

    Safety of JAK inhibitors (JAKi) in chronic inflammatory arthritis (CIA): an observational study

    Clara De Miguel1, Héctor Vega2, Marta Sánchez2, Esther Toledano3, Pedro Pablo Bermejo4, Leonor Laredo5, José Alberto Peña6, María Teresa Benítez7, DALIFER FREITES8, LETICIA LEON9 and lydia Abasolo Alcazar10, 1Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, 2Complutense University of Madrid, Madrid, Spain, 3Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, 4Clinical Pharmacology Service, San Carlos Clinical Hospital, MADRID, Madrid, Spain, 5Hospital Clinico San Carlos, MADRID, Madrid, Spain, 6Pharmacy Service San Carlos Clinical Hospital, MADRID, Madrid, Spain, 7San Carlos Clinical Hospital, MADRID, Madrid, Spain, 8Rheumatology Service, San Carlos Clinical Hospital, Madrid, Madrid, Spain, 9Fundación Investigación Biomédica Hospital Clínico San Carlos, IdISSC; Universidad Camilo Jose Cela, MADRID, Madrid, Spain, 10IdISSC. HCSC, Madrid, Madrid, Spain

    Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA) are chronic inflammatory arthritis (CIAs). Janus kinase inhibitors (JAKis) have emerged as a promising therapeutic…
  • Abstract Number: 0582 • ACR Convergence 2025

    Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India

    Prabhu Vasantha Kumar1, John Mathew2, Ashish Jacob Mathew3 and Ruchika Goel2, 1Christian Medical College, Vellore, Tamil Nadu, India, Vellore, Tamil Nadu, India, 2Christian Medical College, Vellore, Tamil Nadu, India, 3Christian Medical College, Vellore, India

    Background/Purpose: Despite the good efficacy of bDMARDs in nearly 60% of patients with axial spondyloarthritis (AxSpA), high costs limit their use in resource-limited settings. Few…
  • Abstract Number: 2361 • ACR Convergence 2025

    Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis

    Mark Hwang1, Seokhun Kim2, Shervin Assassi3, Joyce Samuel1, Charles Green1, Jon Tyson2 and John Reveille4, 1UTHealth Houston, Houston, TX, 2UTHealth Houston, Houston, 3Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, 4Department of Medicine, University of Texas Medical Center, Houston, TX

    Background/Purpose: We previously reported primary outcomes from a Bayesian series of N-of-1 trials comparing celecoxib, meloxicam, and naproxen in axial spondyloarthritis (axSpA), demonstrating improved ASDAS…
  • Abstract Number: 2321 • ACR Convergence 2025

    Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis

    Martín Valdez-López1, Ana Barrera-Vargas1, Javier Merayo-Chalico2, Irazú Contreras-Yañez3, Carlos Abdiel Abitia Borboa4, Iris Paola García-Herrera1, Raúl Pérez-Gamboa1 and Guillermo Arturo Guaracha-Basáñez1, 1Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Distrito Federal, Mexico, 2Reumátika, Centro de Vanguardia en Reumatología, Ciudad de México, Federal District, Mexico, 3Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Tlalpan, Mexico, 4Universidad Autónoma de Sinaloa Facultad de Medicina Culiacán, Culiacan, Sinaloa, Mexico

    Background/Purpose: Spondyloarthritis (SpA) impacts patient’s life, including functionality, QoL, emotional state, and sexual function. The current study was conducted to determine the frequency of sexual…
  • Abstract Number: 1958 • ACR Convergence 2025

    Longitudinal analysis on imaging outcomes: should we use the individual scores from multiple readers or rather the consensus or average of readers?

    Liese de Bruin1, Floris A. van Gaalen1, Manouk de Hooge2, Miranda van Lunteren1, Mary Lucy Marques3, Monique Reijnierse4, Roberta Ramonda5, Inger Jorid Berg6, Carl Turesson7, Robert Landewé8, Désirée Van Der Heijde1 and Sofia Ramiro9, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 3Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands; and Coimbra Local Health Unit, Coimbra, Portugal, 4Department of Radiology, Leiden University Medical Center, Leiden, Netherlands, 5Rheumatology Unit-DIMED-University of Padova ITALY, Padova, Padua, Italy, 66Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Nepal, 7Lund University, Malmö, Sweden, 8Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands; and Zuyderland Medical Center, Heerlen, Netherlands, 9Leiden University Medical Center, Bunde, Netherlands

    Background/Purpose: Imaging outcomes are often evaluated using longitudinal analysis based on scores from multiple readers. However, the input into the analysis can vary from the…
  • Abstract Number: 1438 • ACR Convergence 2025

    Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension

    Félicie Costantino1, Ann-Sophie De Craemer2, Filip Van den Bosch2, Maxime Breban3, Vanessa Taieb4, Diana Voiniciuc5, Natasha de Peyrecave6, Dirk Elewaut7 and Maria-Antonietta D'Agostino8, 1Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR 1173, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, 2Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, 3CHU Ambroise-Paré, Boulogne-Billancourt, France, 4UCB, Colombes, France, 5UCB, Slough, United Kingdom, 6UCB, Brussels, Belgium, 7VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, 8Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy

    Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…
  • Abstract Number: 1041 • ACR Convergence 2025

    Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model

    Edwin Jauregui1, Deisy Restrepo2, Belcy Garzon2, Alexis Atuesta2, Nestor Correa2, Jessica Barrera2 and Andrea Rubio2, 1Riesgo de fractura S.A, Bogotá, Colombia, 2Riesgo de fractura S.A, Bogotá, Colombia

    Background/Purpose: Dose reduction of biologic therapy (BT) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) has been increasingly implemented in recent years, in accordance…
  • Abstract Number: 0547 • ACR Convergence 2025

    Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study

    Patricia Remalante-Rayco1, Laura Passalent2, Manal Alnasser3, Tina Chim1, Robert Inman1, Nigil Haroon4 and Denis Poddubnyy5, 1University Health Network, Toronto, ON, Canada, 2Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 3King Abdulaziz Medical City, Riyadh, Saudi Arabia, 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, 5Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany

    Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) group has recently introduced a consensus-based definition for difficult-to-manage (D2M) axial spondyloarthritis (axSpA) to identify patients with…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 49
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology